Beta Drugs share price
NSE: BETAPharmaceuticals & BiotechnologySmall Cap
Beta Drugs Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 2017 · Issue price ₹85
Last close ₹1,934.20down ₹43.70 (2.21%)
Share price at the NSE close on 27 Oct 2026. Previous close ₹1,977.90.
27 Oct: open ₹1,977.90, high ₹2,028.00, low ₹1,862.10
52-week range of traded prices to 27 Oct 2026
₹990.10Low, 25 Feb 2026₹2,807.90High, 12 Aug 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 27 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,151 Cr1,305th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 39.78
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.91
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 16.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 60,45338.6% delivered
Results
Standalone, as consolidated accounts are on record for only 7 of the last ten years; ₹ crore.Beta Drugs quarterly results
Quarter to Sep 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹58 Crup 3.91%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹3.71 Crdown 37.44%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 6.4%
Revenue by quarter
Peak revenue ₹58 Cr, quarter to Sep 2026; lowest ₹50 Cr, quarter to Dec 2025
Net profit by quarter, a loss in red
| ₹ crore | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | 50.3 | 54.3 | 55.8 | 58.0 |
| Net profit | 3.3 | 5.3 | 5.9 | 3.7 |
| Net margin | 6.5% | 9.8% | 10.6% | 6.4% |
Standalone. The 4 quarters from Dec 2025, the first on record; the half years before them are below. The latest is shaded.
| ₹ crore | Mar 2025 | Sep 2025 |
|---|---|---|
| Revenue | 102 | 121 |
| Net profit | 2 | 6 |
| Net margin | 2.1% | 4.8% |
Standalone. The half years in the same span that the quarters on record do not fully cover.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹225 Crup 2.38%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹14 Crdown 7.11%
- Net margin
- 6.4%
Revenue by year
Peak revenue ₹225 Cr, year to Mar 2026; lowest ₹51 Cr, year to Mar 2018
Net profit by year, a loss in red
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51 | 58 | 65 | 79 | 125 | – | 198 | 220 | 225 |
| Net profit | 7 | 8 | 7 | 7 | 14 | – | 22 | 15 | 14 |
| Net margin | 13.4% | 13.3% | 10.9% | 8.8% | 11.4% | – | 11.1% | 7.0% | 6.4% |
Standalone. Years to March. The latest is shaded. No results on record for the year to Mar 2023.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMACEUTICAL, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −37.6% | −7.5% | −32.5% | 0.0% |
| 3 years | +23.8% | – | – | 0.0% |
| 5 years | +58.2% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Beta Drugs insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group0 purchases, 1 saleNo purchase₹31 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹31 Cr
- Others: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Beta Drugs competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Beta Drugs in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Solara Active Pharma SciencesSOLARA | 3,072 | 83.16 | 2.14 | +27.3% | – | 2.7% | 6.4% | 0.00% |
 HikalHIKAL | 2,489 | – | 2.08 | −5.4% | −153.4% | −2.7% | 3.5% | 0.30% |
 Fredun PharmaceuticalsFREDUN | 2,452 | – | 8.82 | – | – | – | 18.8% | 0.02% |
 Dishman Carbogen AmcisDCAL | 2,316 | 143.30 | 0.35 | +0.2% | −84.5% | 0.3% | 1.4% | 0.00% |
 Sai ParenteralsSAIPARENT | 2,113 | – | 4.31 | – | – | – | – | 0.00% |
 Sakar HealthcareSAKAR | 2,070 | 48.29 | 5.98 | +48.0% | +119.8% | 13.2% | 16.6% | 0.00% |
 Indoco RemediesINDOCO | 2,037 | 63.77 | 1.99 | +10.8% | – | 3.2% | 1.8% | 0.09% |
 Panacea BiotecPANACEABIO | 1,955 | – | 2.34 | +10.3% | −162.0% | −0.9% | −3.6% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Beta Drugs announcements
Oct 2026
22 Oct · Business
22 Oct · Results
16 Oct · Analysts
15 Oct · Board meeting
Sep 2026
30 Sep · Meeting
Beta Drugs share price by year
Each calendar year to 2025.Beta Drugs share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,549.10 | −22.9% | 2,076.35 | 1,512.80 |
| 2024 | 2,009.00 | +36.7% | 2,251.75 | 1,083.00 |
| 2023 | 1,470.00 | +107.0% | 1,507.35 | 610.00 |
| 2022 | 710.00 | +10.9% | 956.45 | 515.00 |
| 2021 | 640.25 | +437.8% | 640.25 | 112.00 |
| 2020 | 119.05 | +56.9% | 135.30 | 39.00 |
| 2019 | 75.90 | −0.8% | 118.85 | 61.10 |
| 2018 | 76.50 | −59.1% | 202.25 | 58.10 |
| 2017 | 187.25 | – | 198.00 | 93.00 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2017 is from its first session, 12 Oct 2017.
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 26 Oct 2026 | 1,896.00 | 2,035.00 | 1,895.20 | 1,977.90 | 1,982.06 | 75,889 | 33.7% |
| 23 Oct 2026 | 1,973.00 | 1,973.00 | 1,823.00 | 1,894.60 | 1,881.54 | 1,55,586 | 35.7% |
| 22 Oct 2026 | 1,664.70 | 1,997.60 | 1,616.00 | 1,971.00 | 1,878.69 | 5,67,442 | 15.8% |
| 21 Oct 2026 | 1,701.10 | 1,710.00 | 1,629.00 | 1,664.70 | 1,662.53 | 24,978 | 46.5% |
| 19 Oct 2026 | 1,779.80 | 1,779.80 | 1,700.00 | 1,719.60 | 1,736.77 | 18,555 | 46.9% |
| 16 Oct 2026 | 1,786.00 | 1,804.90 | 1,713.50 | 1,783.00 | 1,750.27 | 26,526 | 44.7% |
| 15 Oct 2026 | 1,700.00 | 1,870.00 | 1,674.20 | 1,750.30 | 1,809.59 | 1,61,207 | 28.1% |
| 14 Oct 2026 | 1,686.00 | 1,718.90 | 1,625.00 | 1,699.50 | 1,670.00 | 56,677 | 42.8% |
| 13 Oct 2026 | 1,845.00 | 1,859.40 | 1,660.00 | 1,677.70 | 1,712.68 | 1,25,336 | 54.8% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- BETA
- ISIN
- INE351Y01019
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.betadrugslimited.com